You may not log in without verifying your email address.
Please check your email (including your spam email) for the Welcome message that was sent.
Ziprasidone hydrochloride monohydrate is an atypical antipsychotic that displays combined SR-2A and D2DR inhibition. Ziprasidone displays high affinity at SR-2A receptors with a SR-2A/D2DR affinity ratio greater than any other clinically available atypical antipsychotics (pKi values are 9.38, 8.88, 8.69, 8.47, 8.32, 8.14, 7.98, 7.49, 7.33 and 6.28 for SR-2A, 5-HT2C, 5-HT1D, 5-HT1A, D2DR, D3, α1, D4, H1 and D1 receptors respectively).
Seeger et al (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J.Pharmacol.Exp.Ther. 275 101. Schmidt et al (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur.J.Pharmacol. 425 197. Fell et al (2005) Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav.Brain Res. 160 338.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.